Combined use of epigallocatechin-3-gallate (EGCG) and caffeine in low doses exhibits marked anti-obesity synergy through regulation of gut microbiota and bile acid metabolism.
Ming-Zhi ZhuFang ZhouJian OuyangQi-Ye WangYi-Long LiJian-Lin WuJian-An HuangZhong-Hua LiuPublished in: Food & function (2021)
Epigallocatechin-3-gallate (EGCG) and caffeine constitute the most effective ingredients of weight loss in tea. However, whether combination of EGCG and caffeine exhibits anti-obesity synergy remains unclear. Here, we showed low-doses of EGCG and caffeine used in combination led to synergistic anti-obesity effects equivalent to those of high-dose EGCG. Furthermore, combination treatment exhibited a synergistic effect on altering gut microbiota, including decreased Firmicutes level and increased Bifidobacterium level. Other notable effects of combination treatment included synergistic effects on: increasing fecal acetic acid, propionic acid, and total SCFAs; decreasing expression of GPR43; and increasing microbial bile salt hydrolase gene copies in the gut, facilitating generation of unconjugated BAs and enhancing fecal BA loss. Additionally, combination treatment demonstrated synergistic effects toward increasing the expression of hepatic TGR5 and decreasing the expression of intestinal FXR-FGF15, resulting in increased expression of hepatic CYP7A1. Thus, the synergistic effect may be attributed to regulation of gut microbiota and BA metabolism.
Keyphrases
- weight loss
- poor prognosis
- insulin resistance
- high dose
- type diabetes
- metabolic syndrome
- bariatric surgery
- cancer therapy
- weight gain
- binding protein
- high fat diet induced
- genome wide
- roux en y gastric bypass
- adipose tissue
- gastric bypass
- skeletal muscle
- physical activity
- stem cell transplantation
- combination therapy